Please check your internet connection and try again.
# Sodium Phosphate Enema
## Overview
A hypertonic saline laxative that works by osmotic effect, drawing water into the colonic lumen to soften stool and stimulate evacuation. Onset of action is typically 2–15 minutes.
## Primary Indications
* Relief of occasional constipation.
* Bowel cleansing prior to rectal examinations or surgical procedures.
## Adult Dosing
* **Routine Constipation:** 118 mL (one ready-to-use bottle) administered rectally as a single dose.
* **Maximum:** Do not exceed 1 dose in 24 hours. Prolonged or frequent use may lead to dependency or electrolyte disturbances.
## Pediatric Dosing
* **Children 2–11 years:** 59 mL administered rectally as a single dose.
* **Children <2 years:** Generally **contraindicated** due to high risk of severe electrolyte toxicity (hyperphosphatemia, hypocalcemia, hypernatremia).
* *Note: Always verify local institutional protocols as formulations and concentrations vary.*
## Dose Adjustments
* **Renal Impairment:** Use with extreme caution. There is a high risk of hyperphosphatemia and hypocalcemia in patients with chronic kidney disease.
* **Hepatic Impairment:** No specific adjustment, but monitor for fluid/electrolyte shifts.
## Contraindications
* Known hypersensitivity to sodium phosphates.
* Megacolon (congenital or acquired).
* Gastrointestinal obstruction or perforation.
* Congestive heart failure, clinically significant renal impairment, or ascites (due to potential for profound fluid/electrolyte shifts).
## Adverse Effects
* **Common:** Rectal irritation, abdominal cramping, nausea.
* **Serious:** Severe electrolyte imbalances (hyperphosphatemia, hypocalcemia, hyperkalemia, hypernatremia), dehydration, metabolic acidosis, and acute phosphate nephropathy (calcium phosphate deposition in kidneys).
## Key Drug Interactions
* **Diuretics:** Increased risk of dehydration and electrolyte imbalance.
* **ACE Inhibitors/ARBs/NSAIDs:** Concurrent use may increase the risk of acute phosphate nephropathy or renal injury.
* **Calcium Channel Blockers:** Potential for enhanced hypocalcemia.
## Monitoring
* Monitor serum electrolytes (phosphate, calcium, sodium, potassium) in high-risk patients.
* Observe for signs of dehydration (e.g., poor skin turgor, tachycardia, hypotension).
* Assess fecal return to ensure effective evacuation.
## Clinical Pearls
* **Administration:** Patient should be placed in the left lateral decubitus position (Sims' position) to facilitate movement through the sigmoid colon.
* **Safety:** Do not force the enema tip if resistance is felt, as this may cause rectal perforation.
* **Risk:** Avoid in patients with existing electrolyte abnormalities or those at risk for acute kidney injury.
* **Dehydration:** Ensure adequate oral hydration before and after administration to minimize the risk of hypertonic dehydration.
***
*Disclaimer: This information is for educational purposes and does not replace professional clinical judgment. Always verify current prescribing information, institutional protocols, and patient-specific factors before administering this medication.*
